Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.

Thermo Fisher Scientific Inc. (NYSE:TMO ) Wolfe 2024 Healthcare Results Conference November 19, 2024 8:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Co...

Thermo Fisher Scientific has strong growth prospects due to easing COVID-19 headwinds, improving Chinese and biotech markets, and favorable funding environments. The company's margins should benefi...

Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.

Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contaminat...

Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.

Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T...

Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investment...

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, comp...

Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX). But which of these two stocks is more attractiv...

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.